Welcome to LookChem.com Sign In|Join Free

CAS

  • or

314-19-2

Post Buying Request

314-19-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

314-19-2 Usage

Description

4H-Dibenzo[de,g]quinoline-10,11-diol,5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)-, also known as Apomorphine hydrochloride, is a white or off-white powder or crystal that is soluble in hot water. It is an aporphine alkaloid belonging to the benzoquinoline class. Apomorphine is characterized by its short plasma half-life and significant interpatient variability in its pharmacokinetic profile. It is extensively metabolized through various routes, including sulfation, N-demethylation, glucuronidation, and oxidation.

Uses

Used in Pharmaceutical Industry:
4H-Dibenzo[de,g]quinoline-10,11-diol,5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)is used as an emetic for inducing vomiting in cases of poisoning or drug overdose. It acts as a potent dopamine agonist, stimulating postsynaptic D1and D2-type receptors within the caudate/putamen in the brain.
Used in Parkinson's Disease Treatment:
In the field of neurology, 4H-Dibenzo[de,g]quinoline-10,11-diol,5,6,6a,7-tetrahydro-6-methyl-, hydrochloride (1:1), (6aR)is used as a potential treatment for Parkinson's disease. It is indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable on/off episodes) associated with advanced Parkinson's disease. The brand name for this application is Apokyn, developed by Vernalis.
The various routes of administration for Apomorphine hydrochloride include subcutaneous injection, continuous subcutaneous infusion, intravenous infusion, intranasal spray application, sublingual, and rectal administration. It is highly lipophilic, allowing for rapid diffusion across the blood-brain barrier after injection. Dosage adjustments may be necessary in cases of liver and renal impairment.

Originator

Apomorphine hydrochloride,Nastech Pharmaceuticals Company, Inc.

Manufacturing Process

2 Methods of producing of apomorphine 1. The apomorphine was obtained by dehydratation of morphine at heating to 120°C in the presence phosphoric acid and rendering of HCl gas over reaction mixture. 2. The morphine was converted to β-chloromorphine and then to dichlorodihydrodesoxymorphine at heating to 140°-150°C in the presence hydrochloric acid. Then apomorphine is obtained by dehydratation of dichlorodihydrodesoxymorphine.

Therapeutic Function

Emetic, Expectorant, Hypnotic, Antiparkinsonian, Dopamine agonist

Biological Activity

Prototypical dopamine agonist (pK i values are 6.43, 7.08, 7.59, 8.36 and 7.83 for human recombinant D 1 , D 2L , D 3 , D 4 and D 5 receptors respectively). Produces biphasic effects on locomotor activity, and displays anti-Parkinsonian and neuroprotective actions following systemic administration in vivo .

Clinical Use

Treatment of refractory motor fluctuations in Parkinson’s disease

Safety Profile

Poison by intravenous andintraperitoneal routes. Mutation data reported. When heated to decomposition itemits very toxic fumes of NOx and HCl.

Veterinary Drugs and Treatments

Apomorphine is used primarily as an emetic in dogs, and is considered the emetic of choice for dogs by many clinicians. It is sometimes used in cats, but its use in this species is somewhat controversial.

Drug interactions

Potentially hazardous interactions with other drugs Antihypertensives: enhanced hypotensive effect. Domperidone: possible increased risk of ventricular arrhythmias. 5HT3 -receptor antagonists: possibly increased hypotensive effects with ondansetron. Nitrates: enhanced hypotensive effect.

Metabolism

After subcutaneous injection its fate can be described by a two-compartment model, with a distribution half-life of 5 (±1.1) minutes and an elimination half-life of 33 (±3.9) minutes. Clinical response correlates well with levels of apomorphine in the cerebrospinal fluid. Apomorphine is extensively metabolised in the liver, mainly by conjugation with glucuronic acid or sulfate; the major metabolite is apomorphine sulfate. It is also demethylated to produce norapomorphine. Most of a dose is excreted in urine, mainly as metabolites.

Check Digit Verification of cas no

The CAS Registry Mumber 314-19-2 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 3,1 and 4 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 314-19:
(5*3)+(4*1)+(3*4)+(2*1)+(1*9)=42
42 % 10 = 2
So 314-19-2 is a valid CAS Registry Number.
InChI:InChI=1/C17H17NO2.ClH/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12;/h2-6,13,19-20H,7-9H2,1H3;1H

314-19-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name (R)-(-)-Apomorphine hydrochloride,(R)-5,6,6a,7-Tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diolhydrochloride

1.2 Other means of identification

Product number -
Other names 4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, (R)-

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:314-19-2 SDS

314-19-2Relevant articles and documents

PRODUCTION PROCESS OF A HYDROCHLORIC ACID SALT OF APOMORPHINE AND DERIVATIVES THEREOF

-

Page/Page column 14; 15; 16, (2021/05/07)

The present invention provides processes for the preparation of a hydrochloric acid salt of compound of formula (2): (I) Compound of formula (2) wherein: R1 is selected from the group consisting of -H, an unsubstiuted straight-chain C1-C20-alkyl, substituted straight-chain C1-C20-alkyl, unsubstituted branched -chain C1-C20-alkyl, substituted branched-chain C1-C20-alkyl, unsubstituted cyclic C3-C20-alkyl, and substituted cyclic C3-C20-alkyl; and R2 is selected from the group consisting of an unsubstituted straight-chain C1-C20-alkyl, substituted straight-chain C1-C20-alkyl, unsubstituted branched-chain C1-C20-alkyl, substituted branched-chain C1-C20-alkyl, unsubstituted cyclic C3-C20-alkyl, substituted cyclic C3-C20-alkyl, unsubstituted -C1-20-alkyl-C3-20-cycloalkyl, substituted -C1-20-alkyl-C3-20-cycloalkyl, unsubstituted allyl and substituted allyl.

FACILE 'ONE POT' PROCESS FOR APOMORPHINE FROM CODEINE

-

Page/Page column 5, (2009/04/25)

An improved method for producing apomorphine and derivatives thereof is provided. The method is a convenient 'one-pot' process, comprising the conversion of codeine into apomorphine without isolating the apocodeine intermediate. Use of water reactive scavengers, reagents that will react irreversibly with water, decreases side product formation and allows the use of milder reaction conditions. This one-pot synthesis of apomorphine from codeine provides a faster reaction with improved yields at temperatures lower as compared to conventional methods. The lower operating temperatures and less volatile reactants make the method particularly useful for large-scale manufacturing.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 314-19-2